43 results on '"Greene,Mallik"'
Search Results
2. Real-world multi-target stool DNA adherence in an underserved and vulnerable prison patient population.
3. Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy
4. Medication Adherence, Health Care Utilization, and Costs in Patients With Major Depressive Disorder Initiating Adjunctive Atypical Antipsychotic Treatment
5. Health Care Resource Use, Costs, and Diagnosis Patterns in Patients With Schizophrenia and Bipolar Disorder: Real-world Evidence From US Claims Databases
6. The economic burden of bipolar I disorder in the United States in 2015
7. Earlier Versus Later Augmentation with an Antipsychotic Medication in Patients with Major Depressive Disorder Demonstrating Inadequate Efficacy in Response to Antidepressants: A Retrospective Analysis of US Claims Data
8. Correction to: The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey
9. Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data
10. Synergistic effects of social media and traditional marketing on brand sales: capturing the time-varying effects
11. Impact of Atypical Antipsychotics as Adjunctive Therapy on Psychiatric Cost and Utilization in Patients with Major Depressive Disorder
12. Impact of Atypical Antipsychotics as Adjunctive Therapy on Psychiatric Cost and Utilization in Patients with Major Depressive Disorder
13. Real-World Economic Outcomes of Brexpiprazole and Extended-Release Quetiapine Adjunctive Use in Major Depressive Disorder
14. The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey
15. Systematic literature review on patterns of pharmacological treatment and adherence among patients with bipolar disorder type I in the USA
16. Hospitalization risk factors in antipsychotic-treated schizophrenia, bipolar I disorder or major depressive disorder
17. Early initiation of long-acting injectable antipsychotic treatment is associated with lower hospitalization rates and healthcare costs in patients with schizophrenia: real-world evidence from US claims data
18. Atypical antipsychotic adherence is associated with lower inpatient utilization and cost in bipolar I disorder
19. Evaluation of patient support program and adherence to long-acting injectable aripiprazole for patients utilizing injection local care centers
20. Impact of initiating long-acting injectable antipsychotics on hospitalization in patients with bipolar I disorder
21. A real-world analysis of healthcare costs and relative risk of hyperprolactinemia associated with antipsychotic treatments in the United States
22. Budget impact analysis of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA
23. Cost–effectiveness of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA
24. Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder
25. S107. HEALTHCARE UTILIZATION AND COST IN SCHIZOPHRENIA AND BIPOLAR DISORDER: REAL-WORLD EVIDENCE FROM US CLAIMS DATABASES
26. O8.5. SCHIZOPHRENIA AND BIPOLAR DISORDER DIAGNOSIS PATTERNS: REAL-WORLD EVIDENCE FROM US CLAIMS DATABASES
27. F75. MEDICATION ADHERENCE AND DISCONTINUATION IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH ARIPIPRAZOLE ONCE-MONTHLY LONG-ACTING INJECTABLE VERSUS THOSE TREATED WITH ORAL ANTIPSYCHOTICS
28. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder
29. PP029 Hospitalizations And Costs In Bipolar Disorder Patients Initiating Long-acting Injectable Antipsychotics
30. PP040 Hospitalization Costs In Schizophrenia: Long-acting Injectable Antipsychotics Versus Oral Antipsychotic Use
31. VP51 Hospitalizations And Costs In Schizophrenia Patients Initiating Long-acting Injectable Antipsychotics
32. Evaluation of patient support program and adherence to long-acting injectable aripiprazole for patients utilizing injection local care centers.
33. Atypical antipsychotic adherence is associated with lower inpatient utilization and cost in bipolar I disorder.
34. Modeling the Dynamics on the Effectiveness of Marketing Mix Elements
35. Synergistic effects of social media and traditional marketing on brand sales: capturing the time-varying effects
36. All-cause hospitalization and associated costs in patients with schizophrenia or bipolar disorder initiating long-acting injectable antipsychotics.
37. Outcomes Associated with Nonconcordance to National Kidney Foundation Guideline Recommendations for Oral Antidiabetic Drug Treatments in Patients with Concomitant Type 2 Diabetes and Chronic Kidney Disease
38. Evaluation of the Prevalence of Chronic Kidney Disease and Rates of Oral Antidiabetic Prescribing in Accordance with Guidelines and Manufacturer Recommendations in Type 2 Diabetic Patients within a Long-Term Care Setting
39. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder
40. Evaluation of the Prevalence of Chronic Kidney Disease and Rates of Oral Antidiabetic Prescribing in Accordance with Guidelines and Manufacturer Recommendations in Type 2 Diabetic Patients within a Long-Term Care Setting.
41. PP040 Hospitalization Costs In Schizophrenia: Long-acting Injectable Antipsychotics Versus Oral Antipsychotic Use.
42. PP029 Hospitalizations And Costs In Bipolar Disorder Patients Initiating Long-acting Injectable Antipsychotics.
43. VP51 Hospitalizations And Costs In Schizophrenia Patients Initiating Long-acting Injectable Antipsychotics.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.